<p>Disclosed is a pharmaceutical composition for treating and/or preventing abnormalities of bone metabolism, which targets a protein encoded by a gene that can be strongly expressed in osteoclasts. Specifically disclosed are: a pharmaceutical composition containing an antibody that can recognize human Siglec-15 specifically and has an activity of inhibiting the formation of osteoclasts; and others.</p>